Form 483

Teva Womens Health, LLC Form 483, 2018-01-26

FDA issued a Form 483 to Teva Womens Health, LLC on 2018-01-26 with 8 public-safe observations.

483· Form 483 issuedHuman Drugs8 observations

Teva Womens Health, LLC · Cincinnati, United States · Issued January 26, 2018

Overview

  • 8 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

26 Jan 2018
21 CFR 211.122(a)

Written procedures not followed

Cited by Lindsey M Schwierjohann, Kenneth E Felkley, Nicholas L Paulin

26 Jan 2018
21 CFR 211.122(a)

Written procedures not followed

Cited by Lindsey M Schwierjohann, Kenneth E Felkley, Nicholas L Paulin

26 Jan 2018
21 CFR 211.194(a)(4)

Complete Test Data

Cited by Lindsey M Schwierjohann, Kenneth E Felkley, Nicholas L Paulin

26 Jan 2018
21 CFR 211.194(a)(4)

Complete Test Data

Cited by Lindsey M Schwierjohann, Kenneth E Felkley, Nicholas L Paulin

26 Jan 2018
21 CFR 211.22(c)

Approve or reject procedures or specs

Cited by Lindsey M Schwierjohann, Kenneth E Felkley, Nicholas L Paulin

Inspected site

TWTeva Womens Health, LLCCincinnati, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.122(a)Cited across public-safe Form 483 observations2x
21 CFR 211.194(a)(4)Cited across public-safe Form 483 observations2x
21 CFR 211.22(c)Cited across public-safe Form 483 observations2x
21 CFR 211.56(a)Cited across public-safe Form 483 observations2x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 8 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere